Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML October 21, 2025
FDA approved Danziten™ (nilotinib with no mealtime restrictions) in 1L Ph+ CP CML and imatinib-treated AP Ph+ CML November 16, 2024
FDA approved Scemblix in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile November 5, 2024
Scemblix® Granted FDA Priority Review For The Treatment Of Adults With Newly Diagnosed CML based on ASC4FIRST Ph 3 study data August 6, 2024
Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia March 19, 2024
Scemblix Shows Superior MMR Rates Vs. SoC TKIs In Ph 3 Trial For Newly Diagnosed Patients With CML January 10, 2024
Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States July 12, 2023
